Baroreceptor Activation Therapy 2 Decades after Vascular Surgery on Both Carotid Arteries in a Patient with Resistant Hypertension: First Case Report in the Literature

2018 ◽  
Vol 51 ◽  
pp. 326.e5-326.e8 ◽  
Author(s):  
Christoph H. Blanke ◽  
Frank Willeke ◽  
Michael Buerke ◽  
Ibrahim A. Darwich
Keyword(s):  
Case Report ◽  
Vascular Surgery ◽  
Resistant Hypertension ◽  
Carotid Arteries ◽  
First Case ◽  
Baroreceptor Activation Therapy ◽  
Activation Therapy ◽  
Baroreceptor Activation

Interventional Therapies for Resistant Hypertension: A Brief Update

2016 ◽  
Vol 11 (1) ◽  
pp. 65
Author(s):  
Lisa Brandon ◽  
◽  
◽  
Faisal Sharif
Keyword(s):  
Blood Pressure ◽  
Resistant Hypertension ◽  
Management Options ◽  
Arteriovenous Shunts ◽  
Significant Difference ◽  
Activation Therapy ◽  
Renal Artery Denervation ◽  
Baroreceptor Activation ◽  
And Control ◽  
Interventional Therapies

Resistant hypertension remains a clinical challenge with few management options beyond maximisation of medications. Catheterbased renal artery denervation (RDN) was proposed in 2009 as a possible therapy for resistant hypertension and early feasibility trials caused excitement among cardiologists and antihypertensive specialists, showing remarkable and sustained blood pressure reductions. In 2014, enthusiasm for RDN dampened following the SYMPLICITY 3 trial results, which showed no statistically significant difference in blood pressure between the intervention and control arms. However, hope remains for the improved management of resistant hypertension; procedural understanding, technological advancements and alternative targets – such as baroreceptor activation therapy and arteriovenous shunts – may aid the identification of those patients for whom specific interventional therapies will be effective.

Sign in / Sign up

Export Citation Format

Share Document